RESEARCH ARTICLE

HLA high-resolution typing by next-generation sequencing in Pandemrix-induced narcolepsy

Alexander Lind1,*, Omar Ake1, Madeleine Wallenius1, Anita Ramelius1, Marlena Maziarz1, Lue Ping Zhao1, Daniel E. Geraghty2, Lars Palm3, Åke Lernmark1, Helena Elding Larsson1

1 Department of Clinical Sciences Malmö, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden, 2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 3 Section for Paediatric Neurology, Department of Paediatrics, Skåne University Hospital SUS, Malmö, Sweden

* Alexander.lind@med.lu.se

Abstract

The incidence of narcolepsy type 1 (NT1) increased in Sweden following the 2009–2010 mass-vaccination with the influenza Pandemrix-vaccine. NT1 has been associated with Human leukocyte antigen (HLA) DQB1*06:02 but full high-resolution HLA-typing of all loci in vaccine-induced NT1 remains to be done. Therefore, here we performed HLA typing by sequencing HLA-DRB3, DRB4, DRB5, DRB1, DQA1, DQB1, DPA1 and DPB1 in 31 vaccine-associated NT1 patients and 66 of their first-degree relatives (FDR), and compared these data to 636 Swedish general population controls (GP). Previously reported disease-related alleles in the HLA-DRB5*01:01:01-DRB1*15:01:01-DQA1*01:02:01-DQB1*06:02:01 extended haplotype were increased in NT1 patients (34/62 haplotypes, 54.8%) compared to GP (194/1272 haplotypes, 15.3%, p = 6.17E-16). Indeed, this extended haplotype was found in 30/31 patients (96.8%) and 178/636 GP (28.0%). In total, 15 alleles, four extended haplotypes, and six genotypes were found to be increased or decreased in frequency among NT1 patients compared to GP. Among subjects with the HLA-DRB5*01:01:01-DRB1*15:01:01-DQA1*01:02:01-DQB1*06:02:01 haplotype, a second DRB4*01:03:01-DRB1*04:01:01-DQA1*03:02/*03:03:01-DQB1*03:01:01 haplotype (p = 2.02E-2), but not homozygosity for DRB1*15:01:01-DQB1*06:02:01 (p = 7.49E-1) conferred association to NT1. Alleles with increased frequency in DQA1*01:02:01 (p = 1.07E-5) and DQA1*03:02/*03:03:01 (p = 3.26E-5), as well as with decreased frequency in DRB3*01:01:02 (p = 8.09E-5), DRB1*03:01:01 (p = 1.40E-5), and DQB1*02:01:01 (p = 1.40E-5) were found among patients compared to their FDR. High-resolution HLA sequencing in Pandemrix-associated NT1 confirmed the strong association with the DQB1*06:02:01-containing haplotype but also revealed an increased association to the not previously reported extended HLA-DRB4*01:03:01-DRB1*04:01:01-DQA1*03:02/*03:03:01-DQB1*03:01:01 haplotype. High-resolution HLA typing should prove useful in dissecting the immunological mechanisms of vaccination-associated NT1.
**Introduction**

Narcolepsy type 1 (NT1) is a chronic disease characterized by excessive daytime sleepiness and disturbed nocturnal sleep [1, 2]. The underlying cause behind NT1 is a specific degeneration of the hypocretin producing neurons in the lateral hypothalamus [3, 4]. The cell loss, together with the near-complete association to *Human leukocyte antigen* (HLA) *DQB1*’:06:02 [5], suggests an autoimmune etiology. Historically, it has been difficult to fulfill criteria for autoimmunity in narcolepsy through the identification of autoantigens or disease-specific autoantibodies [6] as well as a disease-related appearance of hypothalamic immune-cell infiltration [2]. Recent studies have identified autoreactive T cells against hypocretin neurons and peptides in NT1 [7–9]. The *HLA-DQB1*’:06:02 allele is present in about 20% of the general European population; it is more common in northern than in southern countries [5]. Consequently, *HLA-DQB1*’:06:02 has been considered as a necessary but not sufficient genetic factor for NT1, since this allele is common in the population, and the incidence of the disease is low. In *HLA-DQA1*’:01:02- *DQB1*’:06:02 heterozygous individuals, *HLA-DQB1*’:03:01 was linked to spontaneous NT1 as the second allele. In contrast, *HLA-DQA1*’:01:01- *DQB1*’:05:01, *DQA1*’:01:03- *DQB1*’:06:03, and *DQA1*’:01:03- *DQB1*’:06:01 were decreased in frequency among NT1-patients as the second haplotype to *DQA1*’:01:02- *DQB1*’:06:02 [5, 10–15].

The Pandemrix-vaccination in Sweden and Finland following the 2009 influenza pandemic resulted in an up to 15-fold increased incidence of NT1 in both countries [16–21]. Moreover, an increased incidence of NT1 was reported in China following the 2009 influenza pandemic [22, 23]. Follow-up studies suggest differences between pre- and post-2009 pandemic NT1 patients in their underlying *HLA* genetics, decreased frequency of *HLA-DQB1*’:06:02 homozygosity and *HLA-DQB1*’:03:01 associated with a young age at onset [10]. *HLA-DQB1* allelic variants associated with NT1 appear comparable between Pandemrix-induced and spontaneous disease [24], but the full *HLA* genetics for vaccine-induced NT1 remains to be determined. It is currently not known whether Pandemrix-associated NT1 share all *HLA* characteristics with spontaneous NT1. To address this question, this study aimed to determine *HLA-DRB3, DRB4, DRB5, DRB1, DQA1, DQB1, DPA1, and DPB1* by high-resolution sequencing [25–27] in 31 Pandemrix-associated NT1 patients, 66 first-degree relatives (FDR), and 636 Swedish general population controls (GP).

**Materials and methods**

**Study populations**

In collaboration with the Swedish Narcolepsy Association, families with one member affected by Pandemrix-induced NT1 were informed about the study and gave consent to participate. The legally authorized representatives, parents or guardians of under aged study participants gave informed consent. In total, 31 patients and 66 FDR, geographically scattered all over Sweden, agreed to donate blood samples at their local Health Center. To the best of our knowledge, the patients had cataplexies and were treated accordingly.

The Swedish population controls (n = 448) subjected to high-resolution HLA typing were reported previously [27] and added to LifeGene ([https://www.lifegene.se/For-scientists/About-LifeGene/](https://www.lifegene.se/For-scientists/About-LifeGene/)) population controls (n = 188), representing the control group (GP, n = 636) in the present study. The LifeGene controls were sequenced simultaneously with the NT1 families. The present study is part of the AMINA-Study (Autoimmune Multiple Sclerosis and Narcolepsy), a Swedish research project focused on neurological autoimmune diseases. The study was approved by the Regional Ethical Review Board in Lund, Sweden (dnr 2015/257). All study participants gave written consent to participate.
DNA extraction

DNA from all participants (n = 97) in the NT1 families were extracted using a QIAamp Blood Maxi Kit (Qiagen) according to the manufacturer’s instructions. Two 8 mL CPT Mononuclear Cell Preparation Tubes (ref 362 761, Becton Dickinson, Franklin Lakes, New Jersey, U.S.) of whole blood were collected, and DNA was extracted from the remaining erythrocyte layer in the tubes following Peripheral Blood Mononuclear cell (PBMC) isolation. CPT tubes were centrifuged for 5 min at 2000 rpm to free the erythrocyte layer underneath the gel plug. The blood clots were lysed in 0.5 mL Qiagen protease and 6 mL DNA purification AL lysis buffer according to the manufacturer’s instructions. Incubation for 10 min in a 70˚C water-bath was followed by the addition of 5 mL 99.5% ethanol. The reaction mixture was applied into QIAamp maxi columns; DNA was bound to the filter during 3 min centrifugation at 4000 rpm. The eluate was discarded and the columns were washed in 5 mL washing buffers AW1 followed by AW2. DNA was eluted in two steps by the addition of 2 × 600 μL Buffer AE and later pooled. The DNA concentration was measured using a Nanodrop device (Thermo Fisher Scientific, Waltham, MA, USA). All samples were diluted in nuclease-free water to a concentration of 50 ng/μL DNA.

HLA high-resolution sequencing

HLA Class II - DRB3, DRB4, DRB5, -DRB1, -DQA1, -DQB1, -DPA1, and -DPB1 typing was carried out using the ScisGo HLA v4 typing kit (Scisco Genetics Inc., Seattle, WA). Briefly, the method employs an amplicon-based 2-stage PCR, followed by sample pooling and sequencing using a MiSeq v2 PE500 (Illumina, San Diego, CA) [25–27]. The inheritance by descent within the NT1 families allowed us to decipher the extended HLA-DRB3, DRB4, DRB5, DRB1, DQA1, DQB1, DPA1, and DPB1 haplotypes. The extended HLA haplotypes for GP were assembled based on the haplotypes identified by descent in the NT1 families. The process to assemble the extended haplotypes of the GP subjects were performed as follows (S1 Table);

1. Homozygous individuals were identified.
2. Individuals heterozygous for HLA-DRB5*01:01:01-DRB1*15:01:01-DQA1*01:02:01-DQB1*06:02:01 were identified. These alleles were assigned to the first haplotype; the remaining alleles were assigned to the second haplotype.
3. Step 2 revealed additional extended haplotypes among individuals heterozygous for HLA-DRB5*01:01:01-DRB1*15:01:01-DQA1*01:02:01-DQB1*06:02:01. A total of sixteen extended haplotype variants were identified.
4. A total of 634/636 control subjects could be assigned to two extended haplotypes according to the scheme in step 3 (S1 Table). Conflicting results were found for two individuals; in both cases, the two extended haplotypes were matched to the same HLA-DRB3, DRB4, DRB5 allele and not matched to the other. This was solved by assigning the matched HLA-DRB3, DRB4, and DRB5 alleles to the more common haplotype.

The Swedish populations’ controls (n = 448) [27] and LifeGene controls (n = 188) were sequenced at two separate occasions with improved typing resolution the second time. As a consequence, DQA1*03:02 for the former group could be separated into DQA1*03:02:01 and DQA1*03:03:01 in the latter group. To be able to merge the groups and compare the controls to NT1-families (typed at the same time as LifeGene controls), the DQA1*03:02 allele was considered as one common DQA1*03:02/*03:02:01/*03:03:01 allele. To simplify the reading of the manuscript, the group was abbreviated to DQA1*03:02/*03:03:01.
Statistical analyses

**RPEs.** Relative predispositional effect analysis was performed as previously described [28]. The analysis was performed with the \( \chi^2 \) test or Fisher’s exact test using R-studios and the package “epiDisplay” (https://cran.r-project.org/web/packages/epiDisplay/epiDisplay.pdf).

In brief, the allele with the largest deviation between groups was identified and excluded. This sequential elimination of most significant effect was repeated in a new round of calculations. The procedure was redone until no further alleles with a significant deviation between the compared groups could be identified. For this analysis, alleles with a low number of narcolepsy-patients \((\leq 1)\) were not considered significant.

**Haplo.score.** Calculations were performed using R-studios and the function “haplo.cc” (http://cran.r-project.org/web/packages/haplo.stats/index.html), as previously described [27, 29, 30].

In brief, allelic frequencies were compared between NT1 patients to GP or FDR. Allelic/haplotypic associations were assessed using Haplotype-score test. Odds ratios were computed following selection of a reference allele/haplotype with a comparable frequency in both patients and controls. The odds ratio for the reference allele/haplotype was 1, higher and lower values being associated with increased and decreased risk, respectively.

Results

The present analysis represents next-generation high-resolution sequencing extended to both exons 2 and 3 for all HLA-DR, DQ, and DP alleles. The analyses follow the allele location on chromosome 6, and allele frequencies are followed by haplotypes, extend haplotypes and genotypes.

**HLA-DRB3, DRB4, DRB5 alleles**

The typing of HLA-DRB3, DRB4, and DRB5 revealed ten alleles with a frequency of at least 1% among NT1 patients or general population controls (GP) (S2 Table). A total of seven HLA-DRB3, DRB4, and DRB5 alleles were found only among GP and with a frequency below 1% (S3 Table). Relative predispositional effects (RPEs) showed that DRB5’01:01:01, DRB4’01:03:01 and DRB3’03:01:01 were associated to NT1 compared to GP (Table 1 and S4 Table). HLA-DRB3’01:01:02 were found at a lower frequency among NT1 patients than among FDRs (Table 1 and S5 Table).

Although not revealed in the RPE analysis, it was observed in the haplo.score analysis that DRB3’01:01:02 and non-amplified HLA-DRB3, DRB4, and DRB5 were negatively associated with NT1 patients compared to GP (S2 Table). HLA-DRB5’01:01:01 was observed with increased frequency for patients compared to FDR (S6 Table).

**HLA-DRB1 alleles**

Twenty different alleles of HLA-DRB1 were found at a frequency of >1% among patients or GP (S2 Table); 24 different HLA-DRB1 alleles were found only among GP at a frequency lower than 1% (S3 Table). The RPE analysis with sequential elimination of each HLA-DRB1 allele with the strongest association showed that DRB1’15:01:01, DRB1’04:01:01, and DRB1’13:02:01 were associated with NT1 (Table 1 and S4 Table). HLA-DRB1’03:01:01 was found at a lower frequency among NT1 patients than among FDR (Table 1 and S5 Table).

Although not revealed in the RPE analysis, it was observed in the haplo.score analysis that HLA-DRB1’01:01:01, DRB1’03:01:01, and DRB1’13:01:01 were negatively associated with
Table 1. RPE analysis of HLA-DRB3, DRB4, DRB5, DRB1, DQA1, DQB1, DPA1, and DPB1 allele frequencies among NT1 patients (n = 31), population controls (n = 636) and first-degree relatives (FDR, n = 66).

| Allele      | Controls n (%) | NT1 n (%) | OR (95% CI)            | p-value  | p-value  | p-value  |
|-------------|----------------|-----------|------------------------|----------|----------|----------|
| DRB3*03:01:01 | 56 (4.4%)      | 4 (6.5%)  | 1.5 (0.38, 4.26)       | 3.57E-01 | 6.21E-02 | 2.32E-02 |
| DRB4*01:03:01 | 307 (21%)      | 13 (21%)  | 0.83 (0.45, 1.56)      | 5.68E-01 | 4.26E-02 |          |
| DRB5*01:01:01 | 205 (16.1%)    | 34 (54.8%)| 6.32 (3.75, 10.65)     | 8.24E-15 |          |          |
| DQB1*04:01:01 | 126 (9.9%)     | 7 (11.3%) | 1.16 (0.52, 2.6)       | 7.22E-01 | 3.42E-02 |          |
| DRB1*13:02:01 | 56 (4.4%)      | 4 (6.5%)  | 1.5 (0.38, 4.26)       | 3.57E-01 | 6.16E-02 | 3.64E-02 |
| DQB1*15:01:01 | 202 (15.9%)    | 34 (54.8%)| 6.43 (3.82, 10.84)     | 4.17E-15 |          |          |
| DQA1*01:02:01 | 265 (20.8%)    | 38 (61.3%)| 6.02 (3.55, 10.21)     | 1.13E-13 |          |          |
| DQA1*03:02/*03:03:01 | 81 (6.4%) | 9 (14.5%) | 2.5 (1.19, 5.24) | 1.25E-02 | 4.36E-07 |          |
| DQB1*03:01:01 | 203 (16%)      | 11 (17.7%)| 1.14 (0.58, 2.22)      | 7.09E-01 | 7.32E-03 |          |
| DQB1*06:02:01 | 201 (15.8%)    | 34 (54.8%)| 6.47 (3.84, 10.91)     | 3.31E-15 |          |          |
| DQB1*06:04:01 | 52 (4.1%)      | 4 (6.5%)  | 1.62 (0.41, 4.63)      | 3.26E-01 | 4.97E-02 | 1.84E-02 |
| DPA1*02:06    | 6 (0.5%)       | 3 (4.8%)  | 10.68 (1.69, 61.4)     | 6.58E-03 |          |          |
| DPB1*02:01:02 | 178 (14%)      | 3 (4.8%)  | 0.31 (0.06, 0.98)      | 3.66E-02 | 5.20E-02 | 2.42E-02 |
| DPB1*04:02:01 | 152 (11.9%)    | 2 (3.2%)  | 0.25 (0.03, 0.94)      | 3.90E-02 | 3.81E-02 |          |
| DQB1*23:01:01 | 4 (0.3%)       | 2 (3.2%)  | 10.51 (0.93, 75.02)    | 2.83E-02 |          |          |
| FDR n (%)     | NT1 n (%)      |           |                        |          |          |          |
| DRB3*01:01:02 | 18 (13.6%)     | 1 (1.6%)  | 0.1 (0, 0.69)          | 8.09E-03 |          |          |
| DRB1*03:01:01 | 16 (12.1%)     | 1 (1.6%)  | 0.12 (0, 0.81)         | 1.40E-02 |          |          |
| DQA1*01:02:01 | 55 (41.7%)     | 38 (61.3%)| 2.22 (1.2, 4.11)       | 1.07E-02 |          |          |
| DQA1*03:02/*03:03:01 | 13 (9.8%) | 9 (14.5%) | 1.55 (0.63, 3.86) | 3.39E-01 | 3.26E-02 |          |
| DQB1*02:01:01 | 16 (12.1%)     | 1 (1.6%)  | 0.12 (0, 0.81)         | 1.40E-02 |          |          |

NT1 compared to GP (S2 Table). DRB1*15:01:01 was observed to be associated with NT1 compared to FDR (S6 Table).

**HLA-DQA1 alleles**

Thirteen different alleles of **HLA-DQA1** were found among NT1 patients or GP in a frequency >1% (S2 Table). Also, ten different **HLA-DQA1** alleles were found only among GP in a frequency lower than 1% (S3 Table).

RPEs analysis revealed that DQA1*01:02:01 and DQA1*03:02/*03:03:01 were associated with NT1 compared to GP (Table 1 and S4 Table) and FDR (Table 1 and S5 Table).

Not revealed by RPE, it was observed in the haplo.score analysis that DQA1*05:01:01 were negatively associated with NT1 patients compared to GP (S2 Table) and FDR (S6 Table). Lower allele frequency among patients compared to GP were observed for DQA1*01:01:01, DQA1*03:03:01, and DQA1*03:03:01 (S2 Table).

**HLA-DQB1 alleles**

Twelve different alleles of **HLA-DQB1** were found among patients or GP in a frequency of at least >1% (S2 Table). Twelve additional alleles were found only among GP and at a frequency lower than 1% (S3 Table). RPE analysis with sequential elimination of each **HLA-DQB1** allele with the strongest association showed that DQB1*06:02:01, DQB1*03:01:01 and DQB1*06:04:01 were associated with NT1 (Table 1 and S4 Table). DQB1*02:01:01 were found at a lower frequency among NT1 patients than among FDRs (Table 1 and S5 Table).

Although not detected in the RPE analysis, it was noted that **HLA-DQB1***02:01:01, DQB1*05:01:01 and DQB1*06:03:01 were negatively associated with NT1 compared to GP.
Table 2. HLA-DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 haplotype frequencies among NT1 patients (n = 31) and population controls (n = 636).

| HLA-DRB3, DRB4, DRB5-DRB1-DQA1-DQB1 haplotypes | Controls n (%) | NT1 n (%) | OR (95% CI) | p-value | p-value | p-value | p-value |
|-----------------------------------------------|----------------|------------|-------------|---------|---------|---------|---------|
| DRB5*01:01-01-DRB1*15:01:01                   | 201 (15.8%)    | 34 (54.8%) | 6.47 (3.84, 10.91) | 3.31E-15 |         |         |         |
| DRB4*01:03:01-DRB1*04:01:01                   | 123 (9.7%)     | 7 (11.3%)  | 1.19 (0.53, 2.67)  | 6.74E-01 | 2.88E-02 |         |         |
| DRB3*03:01-01-DRB1*13:02:01                   | 55 (4.3%)      | 4 (6.5%)   | 1.53 (0.39, 4.35)  | 3.49E-01 | 5.84E-02 | 3.40E-02 |         |
| DQA1*01:02-01-DQB1*06:02:01                   | 200 (15.7%)    | 34 (54.8%) | 6.51 (3.86, 10.97) | 2.62E-15 |         |         |         |
| DQA1*03:02/DQA1*03:03:01-DRB1*03:01:01        | 56 (4.4%)      | 7 (11.3%)  | 2.76 (1.2, 6.34)   | 1.25E-02 | 8.75E-06 |         |         |
| DQA1*01:02-01-DQB1*06:04:01                   | 52 (4.1%)      | 4 (6.5%)   | 1.62 (0.41, 6.43)  | 3.26E-01 | 4.95E-02 | 2.30E-02 |         |

https://doi.org/10.1371/journal.pone.0222882.t002
The RPE analysis revealed that HLA-DRB5*01:01-01:DRB1*15:01:01-01:02:01-DQB1*06:02:01, HLA-DRB4*01:03:01-DRB1*04:01:01-DQA1*03:02/*03:03-01-DQB1*03:01:01, DRB3*03:03:01-13:02:01-01:02:01-06:04:01 and DRB4*01:03:01-07:01:01-02:01/*02:01-02:02:01 were associated with NT1 (Table 2 and S12 Table).

Although not detected in the RPE analysis, two haplotypes were less common among patients in HLA-DRB3*01:01-02:DRB1*03:01-01:DQA1*05:01-01-DQB1*02:01:01 and non-amplified HLA-DRB3, DRB4, DRB5-DRB1*01:01-01:DQA1*01:01-01:DQB1*05:01:01 (S10 Table). The HLA-DRB5*01:01-01:DRB1*15:01:01-01:02:01-DQB1*06:02:01 extended haplotype was increased among NT1 patients (34/62 haplotypes, 54.8%) compared to GP (194/1272 haplotypes, 15.3%). This extended HLA haplotype was indeed found in 30/31 patients (96.8%) and in 178/636 GP (28.0%).

**HLA-DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 genotypes**

Extended DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 genotypes were compared in NT1 (n = 30) and GP (n = 178) subjects who had the DRB5*01:01-01:DRB1*15:01:01-01:DQA1*02:02-DQB1*06:02 haplotype (S13 and S14 Tables). The DRB4*01:03:01-DRB1*04:01:01-DQA1*03:02/*03:01-01:DQB1*03:01:01 haplotype was associated with NT1, while homozygosity for DRB1*15:01:01-DQB1*06:02:01 was not (Table 3 and S13 and S14 Tables).

In total, 346 different DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 genotypes were found among 667 subjects (31 NT1 patients and 636 GP); 25 genotypes were found among either patients or GP in a frequency of >1% (S15 and S16 Tables). Six extended genotypes were associated to NT1, all had one HLA-DRB5*01:01-01:DRB1*15:01:01-01:DQA1*01:02:01-DQB1*06:02:01 extended haplotype and were paired with either DRB4*01:03:01-DRB1*04:01:01-01:DQA1*03:02/*03:01-01:DQB1*03:01:01, DRB5*01:01-01:DRB1*15:01:01-DQA1*02:02-01:DQB1*06:02:01, DRB3*03:01-01:DRB1*13:02:01-01:DQA1*01:02:02-DQB1*06:04:01, non-amplified HLA-DRB3, DRB4, DRB5-DRB1*08:01:01-DQA1*04:01-01-DQB1*04:02:01, DRB3*02:02-01:DRB1*12:01:01-DQA1*05:05:01-DQB1*03:01:01 or DRB4*01:03:01-DRB1*07:01:01-DQA1*02:01//02:01-01:DQB1*02:02:01 as the second haplotype (Table 3 and S15 Table).

**Table 3. HLA-DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 genotype frequencies among NT1 patients (n = 31) and population controls (n = 636).**

| Genotypes | Controls n (%) | NT1 n (%) | OR (95% CI) | p-value | p-value | p-value | p-value | p-value |
|-----------|----------------|-----------|-------------|---------|---------|---------|---------|---------|
| DRB5*01:01-01-15:01:01-01:02:01-06:02:01-DRB4*01:03:01-01:04:01-01-03:02//03:03-01-03:01:01 | 6 (0.9%) | 5 (16.1%) | 19.89 (4.5, 84.19) | 5.93E-02 | 1.22E-02 | 8.22E-03 | 1.22E-02 | 8.22E-03 |
| DRB5*01:01-01-15:01:01-01:02:01-06:02:01-DRB5*01:01-01:15:01-01:02:01-06:02:01 | 16 (2.5%) | 4 (12.9%) | 5.71 (1.3, 19.4) | 1.10E-02 | 6.11E-02 | 1.22E-02 | 8.22E-03 | 1.22E-02 | 8.22E-03 |
| DRB5*01:01-01-15:01:01-01:02:01-06:02:01-DRB3*03:01-01:13:02:01-01:02:01-06:04:01 | 10 (1.6%) | 3 (9.7%) | 6.66 (1.12, 27.89) | 1.90E-02 | 1.22E-02 | 8.22E-03 | 1.22E-02 | 8.22E-03 | 1.22E-02 | 8.22E-03 |
| DRB5*01:01-01-15:01:01-01:02:01-06:02:01-DRB5*01:03-01-DRBX*null-08:01:01-01:04:01-01:04:01-01:04:02:01 | 6 (0.9%) | 2 (6.5%) | 7.19 (0.68, 12.55) | 4.92E-02 | 3.65E-02 | 2.82E-02 | 2.21E-02 | 2.31E-02 | 2.31E-02 |
| DRB5*01:01-01-15:01:01-01:02:01-06:02:01-DRB3*02:02:01-12:01:01-05:05:01-03:01:01 | 7 (1.1%) | 2 (6.5%) | 6.16 (0.6, 34.34) | 6.14E-02 | 4.38E-02 | 3.55E-02 | 2.79E-02 | 2.31E-02 | 2.31E-02 |
| DRB5*01:01-01-15:01:01-01:02:01-06:02:01-DRB4*01:03-01-07:01:01-01:02:01//02:01-01:02:02:01 | 8 (1.3%) | 2 (6.5%) | 5.39 (0.53, 28.73) | 7.46E-02 | 5.95E-02 | 4.35E-02 | 3.43E-02 | 2.84E-02 | 2.30E-02 | 2.30E-02 |

**HLA-DRB3, DRB4, DRB5-DRB1-DQA1-DQB1 haplotypes among HLA-DRB5*01:01-01-DRB1*15:01:01-01:02:01-01:02:01 heterozygotes**

| Genotypes | Controls n (%) | NT1 n (%) | OR (95% CI) | p-value | p-value | p-value | p-value | p-value |
|-----------|----------------|-----------|-------------|---------|---------|---------|---------|---------|
| DRB4*01:03:01-01-04:01-01-03:02//03:03-01-03:01:01 | 6 (4%) | 5 (16.7%) | 4.77 (1.07, 20.41) | 2.02E-02 | 2.02E-02 | 2.02E-02 | 2.02E-02 | 2.02E-02 | 2.02E-02 |

https://doi.org/10.1371/journal.pone.0222882.t003
Discussion

High-resolution HLA sequencing was used to dissect the association between HLA and NT1 that developed in subjects vaccinated with Pandemrix. The major findings were:

1. The patients (30/31 subjects, 34/62 haplotypes) carried at least one haplotype of DRB5*01:01:01-DRB1*15:01:01-DQA1*01:02:01-DQB1*06:02:01.

2. Among subjects heterozygous for DRB5*01:01:01-DRB1*15:01:01-DQA1*01:02:01-DQB1*06:02:01, the only second haplotype associated with NT1 was DRB4*01:03:01-DRB1*04:01:01-DQA1*03:02/*03:03:01-DQB1*03:01:01 while DRB5*01:01:01-DQA1*01:02:01-DRB1*15:01:01-DQB1*06:02:01 homozygosity was not.

3. Alleles with an increased (DQA1*01:02:01, DQA1*03:02/*03:03:01) and decreased (DRB3*01:01:02, DRB1*03:01:01, DQB1*02:01:01) frequency were associated with the patients compared to their FDR.

Caucasians demonstrate a strong linkage disequilibrium with the haplotype of DRB5*01:01:01-DRB1*15:01:01-DQA1*01:02:01-DQB1*06:02:01 and those haplotypes were found in 30/31 patients in the current study. NT1 was also positively associated with DQA1*03:02/*03:03:01-DQB1*03:01. We speculate that co-inheritance of DQA1*01:02-DQB1*06:02 together with DQA1*03:02/*03:03:01-DQB1*03:01 as secondary haplotype was a characteristic genetic predisposition for Pandemrix-induced NT1. HLA-DQB1*03:01 has previously been reported to associate to NT1 if present as the second allele to DQB1*06:02 [10–13].

The strengths of the present study were the high-resolution HLA typing in a group of Pandemrix-induced NT1 patients and controls both from the general population and the NT1 patients respective immediate family. Using the families, it was possible to ascertain by descent correct extended HLA haplotypes. Our study determined allelic frequencies for patients compared to FDR. Three alleles, DRB3*01:01:02, DRB1*03:01:01, and DQB1*02:01:01 were found at a higher frequency among the FDR compared to the NT1 probands and could have had a protective impact in the etiological process leading to NT1. Although there are few family studies of NT1, it is generally accepted that the disease is non-hereditary. The discordance found among twins suggests other factors that might influence the etiology and pathogenesis of this disease in genetically predisposed individuals [31, 32].

Non-NT1-associated alleles for DQB1 (DQB1*02:01:01, DQB1*05:01:01, DQB1*06:03:01) described in large multi-national non-vaccine related cohorts [5] and among Pandemrix-NT1 patients (DQB1*05:01, DQB1*06:03 and DQB1*06:09) [24] were mostly confirmed in our study. To our knowledge, this is the first study examining the relationships between NT1 and HLA-DRB3, DRB4, and DRB5. Our study found NT1 to be positively associated with DRB5*01:01:01, DRB4*01:03:01, and DRB3*03:01:01. HLA-DRB3, DRB4, and DRB5 genetics have been suggested to have a role in the autoimmune process of type 1 diabetes [27].

HLA-DPA1*01:03-DPB1*04:02 and HLA-DPA1*01:03-DPB1*04:01 were reported to be negatively associated with NT1 [15]. In our Swedish patients, we were able to confirm the decreased frequency of DPB1*04:02:01 among the NT1 patients. In addition, we reported NT1 to be negatively associated with DPB1*02:01:02. The previous [15] and the present report are of interest since HLA-DR associations are suggested to affect the antibody response to influenza vaccination [33]. In addition, DPB1 alleles were related to multiple sclerosis [34], a disease sharing the DRB1*15:01:01-DQB1*06:02:01 association with NT1.

The current study presents what could be interpreted as a seemingly high number of p-values. However, it should be noted first that comparisons of HLA alleles are not independent of
each other. Second, results and p-value of a single allele is replicated in the haplotype and often also in the extended haplotype. For the RPE analysis, the limitation of the small sample size is recognized. It is noted that these results are based on a small sample size and need to be verified independently. Limitations of this study include the lack of follow-up from NT1 genetics to clinical diagnosis and disease severity. NT1 is a complex disease as symptoms, and response to treatments varies in unpredictable ways. HLA-DRB3, -DRB4, and -DRB5 to the DPB1 may have implications to individual patients. As an example, HLA genetics in type 1 diabetes affects the preference of the first autoantibody (IAA or GADA) and has been proposed to be linked to different triggering mechanisms, although both eventually cause beta cell destruction and diabetes [35, 36].

In conclusion, high-resolution HLA class II sequencing demonstrated novel insights into the genetic predisposition to Pandemrix-induced NT1. The finding that the majority of NT1 patients following Pandemrix-vaccination are heterozygous for DQA1*01:02:01-DQB1*06:02:01 and with DQA1*03:02/-DQB1*03:01 as the most common second haplotype suggests that subjects with these HLA combinations have an increased genetic risk for Pandemrix-induced narcolepsy type 1.

Supporting information

S1 Table. Schematic illustration of the assembly process used to create extended haplotypes. (PDF)

S2 Table. Haplo.score analysis of estimated allelic frequencies of HLA-DRB3, DRB4, DRB5, -DRB1, -DQA1, -DQB1, -DPA1, and -DPB1 among NT1 patients and general population controls. (XLSX)

S3 Table. Haplo.score analysis of estimated allelic frequencies of rare (< 1%) HLA-DRB3, DRB4, DRB5,-DRB1, -DQA1, -DQB1, -DPA1, and -DPB1 among NT1 patients and general population controls. (XLSX)

S4 Table. RPE analysis of estimated allelic frequencies of HLA-DRB3, DRB4, DRB5, -DRB1, -DQA1, -DQB1, -DPA1, and -DPB1 among NT1 patients and general population controls. (XLSX)

S5 Table. RPE analysis of estimated allelic frequencies of HLA-DRB3, DRB4, DRB5, -DRB1, -DQA1, -DQB1, -DPA1, and -DPB1 among NT1 patients and FDR. (XLSX)

S6 Table. Haplo.score analysis of estimated allelic frequencies of HLA-DRB3, DRB4, DRB5, -DRB1, -DQA1, -DQB1, -DPA1, and -DPB1 among NT1 patients and FDR. (XLSX)

S7 Table. Haplo.score analysis of estimated frequencies of HLA-DR and HLA-DQ haplotypes among NT1 patients and population controls. (XLSX)
S8 Table. Haplo.score analysis of estimated frequencies of rare (< 1%) HLA-DR and HLA-DQ haplotypes among NT1 patients and population controls.
(XLSX)

S9 Table. RPE analysis of estimated frequencies of HLA-DR and HLA-DQ haplotypes among NT1 patients and population controls.
(XLSX)

S10 Table. Haplo.score analysis of estimated frequencies of HLA-DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 haplotypes among NT1 patients and population controls.
(XLSX)

S11 Table. Haplo.score analysis of estimated frequencies of rare (< 1%) HLA-DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 haplotypes among NT1 patients and population controls.
(XLSX)

S12 Table. RPE analysis of the estimated frequencies of HLA-DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 haplotypes among NT1 patients and population controls.
(XLSX)

S13 Table. RPE analysis of the estimated frequencies of second HLA-DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 haplotypes among DRB5*01:01:01-*15:01:01-*01:02:01-*06:02:01 heterozygotes.
(XLSX)

S14 Table. Haplo.score analysis of the estimated frequencies of second HLA-DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 haplotypes among DRB5*01:01:01-*15:01:01-*01:02:01-*06:02:01 heterozygotes.
(XLSX)

S15 Table. RPE analysis of the estimated frequencies of HLA-DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 genotypes among NT1 patients and population controls.
(XLSX)

S16 Table. Haplo.score analysis of the estimated frequencies of HLA-DRB3, DRB4, and DRB5-DRB1-DQA1-DQB1 genotypes among NT1 patients and population controls.
(XLSX)

Acknowledgments

We would like to acknowledge the NT1 families participating in the study, as well as the Swedish Narcolepsy Association.

Author Contributions

Conceptualization: Alexander Lind, Omar Akel, Madeleine Wallenius, Lue Ping Zhao, Daniel E. Geraghty, Lars Palm, Åke Lernmark, Helena Elding Larsson.

Data curation: Alexander Lind, Anita Ramelius, Lue Ping Zhao.

Formal analysis: Alexander Lind, Omar Akel, Lue Ping Zhao, Daniel E. Geraghty.

Funding acquisition: Alexander Lind, Omar Akel, Åke Lernmark, Helena Elding Larsson.

Investigation: Alexander Lind, Omar Akel, Madeleine Wallenius, Daniel E. Geraghty.
Methodology: Alexander Lind, Omar Akel, Madeleine Wallenius, Anita Ramelius, Marlena Maziarz, Lue Ping Zhao, Daniel E. Geraghty, Åke Lernmark, Helena Elding Larsson.

Project administration: Anita Ramelius, Lars Palm, Åke Lernmark, Helena Elding Larsson.

Resources: Alexander Lind, Omar Akel, Madeleine Wallenius, Anita Ramelius, Daniel E. Geraghty, Lars Palm, Åke Lernmark, Helena Elding Larsson.

Software: Omar Akel, Marlena Maziarz, Lue Ping Zhao, Daniel E. Geraghty.

Supervision: Lars Palm, Åke Lernmark, Helena Elding Larsson.

Validation: Anita Ramelius, Marlena Maziarz, Lue Ping Zhao, Daniel E. Geraghty.

Visualization: Alexander Lind, Anita Ramelius, Lue Ping Zhao, Lars Palm, Åke Lernmark, Helena Elding Larsson.

Writing – original draft: Alexander Lind, Omar Akel, Madeleine Wallenius, Åke Lernmark, Helena Elding Larsson.

Writing – review & editing: Alexander Lind, Omar Akel, Madeleine Wallenius, Anita Ramelius, Marlena Maziarz, Lue Ping Zhao, Daniel E. Geraghty, Lars Palm, Åke Lernmark, Helena Elding Larsson.

References

1. Scammell TE. Narcolepsy. New England Journal of Medicine. 2015; 373(27):2654–62. https://doi.org/10.1056/NEJMra1500587 PMID: 26716917

2. Partinen M, Komrum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. The Lancet Neurology. 2014; 13(6):600–13. Epub 2014/05/23. https://doi.org/10.1016/S1474-4422(14)70075-4 PMID: 24849861.

3. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000; 27(3):469–74. Epub 2000/10/31. https://doi.org/10.1016/s0896-6273(00)00058-1 PMID: 11055430.

4. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature medicine. 2000; 6(9):991–7. Epub 2000/09/06. https://doi.org/10.1038/79690 PMID: 10973318.

5. Tafti M, Hor H, Dauvilliers Y, Lammers GJ, Overeem S, Mayer G, et al. DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with Cataplexy in Europe. Sleep. 2014; 37(1):19–25. https://doi.org/10.5665/sleep.3300 PMID: 24381371

6. Wallenius M, Lind A, Akel O, Karlsson E, Svensson M, Arvidsson E, et al. Autoantibodies in Pandemrix (R)-induced narcolepsy: Nine candidate autoantigens fail the conformational autoantibody test. Autoimmunity. 2019;1–7. Epub 2019/07/23. https://doi.org/10.1080/08916934.2019.1643843 PMID: 31328572.

7. Luo G, Ambati A, Lin L, Bonvalet M, Partinen M, Ji X, et al. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. Proceedings of the National Academy of Sciences of the United States of America. 2018; 115(52):E12323–E32. Epub 2018/12/12. https://doi.org/10.1073/pnas.1818150116 PMID: 30541895.

8. Latorre D, Kallweit U, Armentani E, Foglierini M, Mele F, Cassotta A, et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. 2018; 562(7725):62–8. https://doi.org/10.1038/s41586-018-0540-1 PMID: 30232458

9. Pedersen NW, Holm A, Kristensen NP, Bjerregaard A-M, Bentzen AK, Marquard AM, et al. CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nature communications. 2019; 10(1):837. https://doi.org/10.1038/s41467-019-08774-1 PMID: 30783092

10. Han F, Faraco J, Dong XS, Ollila HM, Lin L, Li J, et al. Genome Wide Analysis of Narcolepsy in China Implicates Novel Immune Loci and Reveals Changes in Association Prior to Versus After the 2009 H1N1 Influenza Pandemic. PLoS Genetics. 2013; 9(10):e1003880. https://doi.org/10.1371/journal.pgen.1003880 PMID: 24204295
11. Han F, Lin L, Li J, Dong SX, An P, Zhao L, et al. HLA-DQ association and allele competition in Chinese narcolepsy. Tissue Antigens. 2012; 80(4):328–35. Epub 2012/08/07. https://doi.org/10.1111/j.1399-0039.2012.01948.x PMID: 22862152.

12. Hor H, Kutalaik Z, Dauvilliers Y, Valtesia A, Lammers GJ, Donjacour CE, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet. 2010; 42(9):786–9. Epub 2010/08/17. https://doi.org/10.1038/ng.647 PMID: 20711714.

13. Hong SC, Lin L, Lo B, Jeong JH, Shin YK, Kim SY, et al. DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans. Human immunology. 2007; 68(1):59–68. Epub 2007/01/09. https://doi.org/10.1016/j.humimm.2006.10.006 PMID: 17207713.

14. Ollila HM, Fernandez-Vina M, Mignot E. HLA-DQ Allele Competition in Narcolepsy: A Comment on Tafti et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep. 2015; 38(1):147–51. https://doi.org/10.5665/sleep.4342 PMID: 25325462.

15. Ollila HM, Ravel JM, Han F, Faraco J, Lin L, Zheng X, et al. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. American journal of human genetics. 2015; 96(1):136–46. Epub 2015/01/13. https://doi.org/10.1016/j.ajhg.2014.12.010 PMID: 25574827.

16. Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology. 2013; 80(14):1315–21. Epub 2013/03/15. https://doi.org/10.1212/WNL.0b013e31828ab26f PMID: 26740600.

17. Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza vaccination. Neurology. 2013; 80(14):1315–21. Epub 2013/03/15. https://doi.org/10.1212/WNL.0b013e31828ab26f PMID: 26740600.

18. Zhao LP, Alshiekh S, Zhao M, Carlsson A, Elding Larsson H, Forsander G, et al. Next Generation Sequencing Reveals That HLA-DRB3, -DRB4, and -DRB5 May Be Associated With Islet Autoantibodies and Risk for Childhood Type 1 Diabetes. Diabetes. 2016; 65(3):710–8. https://doi.org/10.2337/db15-1115 PMID: 26740600.

19. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Annals of neurology. 2011; 70(3):410–7. https://doi.org/10.1002/ana.23799 PMID: 22470453.

20. Partinen M, Saarenpaa-Heikkila O, Iiveskoski I, Hublin C, Linna M, Olsen P, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PloS one. 2012; 7(3):e33723. Epub 2012/04/04. https://doi.org/10.1371/journal.pone.0033723 PMID: 22470463.

21. Hallberg P, Smedje H, Eriksson N, Kohnke H, Danilidou M, Ohman I, et al. Pandemrix-induced narcolepsy is associated with genes related to immunity and neuronal survival. EBioMedicine. 2019. Epub 2019/02/04. https://doi.org/10.1016/j.ebiom.2019.01.041 PMID: 30711515.

22. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Annals of neurology. 2011; 70(3):410–7. https://doi.org/10.1002/ana.22587 PMID: 21866560.

23. Han F, Lin L, Li J, Dong XS, Mignot E. Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. Annals of neurology. 2013; 73(4):560. Epub 2012/12/12. https://doi.org/10.1002/ana.23799 PMID: 23225098.

24. Bomfim IL, Lamb F, Fink K, Szakacs A, Silveira A, Franzén L, et al. The immunogenetics of narcolepsy associated with A(H1N1)pdm09 vaccination (Pandemrix) supports a potent gene–environment interaction. Genes And Immunity. 2017; 18:75. https://doi.org/10.1038/gene.2017.1 PMID: 28332559.

25. Nelson WC, Pyo CW, Vogan D, Wang R, Pyon YS, Hennessey C, et al. An integrated genotyping approach for HLA and other complex genetic systems. Hum Immunol. 2015; 76(12):928–38. Epub 2015/06/02. https://doi.org/10.1016/j.humimm.2015.05.001 PMID: 26027777.

26. Smith AG, Pyo CW, Nelson W, Gow E, Wang R, Shen S, et al. Next generation sequencing to determine HLA class II genotypes in a cohort of hematopoietic cell transplant patients and donors. Hum Immunol. 2014; 75(10):1040–6. Epub 2014/08/30. https://doi.org/10.1016/j.humimm.2014.08.206 PMID: 25167774.

27. Zhao LP, Alsheiek S, Zhao M, Carlsson A, Elding Larsson H, Forsander G, et al. Next-Generation Sequencing Reveals That HLA-DRB3, -DRB4, and -DRB5 May Be Associated With Islet Autoantibodies and Risk for Childhood Type 1 Diabetes. Diabetes. 2016; 65(3):710–8. https://doi.org/10.2337/db15-1115 PMID: 26740600.

28. Payami H, Joe S, Farid NR, Stenszky V, Chan SH, Yeo PP, et al. Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves disease. American journal of human genetics. 1989; 45(4):541–6. PMID: 2491013.
29. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. American journal of human genetics. 2002; 70(2):425–34. Epub 2002/01/16. https://doi.org/10.1086/338688 PMID: 11791212.

30. Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Human heredity. 2003; 55(1):56–65. Epub 2003/08/02. https://doi.org/10.1159/000071811 PMID: 12890927.

31. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998; 50(2 Suppl 1):S16–22. Epub 1998/03/04. https://doi.org/10.1212/wnl.50.2_suppl_1.s16 PMID: 9484418.

32. Dauvilliers Y, Maret S, Bassetti C, Carlander B, Billiard M, Touchon J, et al. A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology. 2004; 62(11):2137–8. Epub 2004/06/09. https://doi.org/10.1212/wnl.62.11.2137 PMID: 15184641.

33. Moss AJ, Gaughran FP, Karasu A, Gilbert AS, Mann AJ, Gelder CM, et al. Correlation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccination. PloS one. 2013; 8(8):e71376. Epub 2013/08/21. https://doi.org/10.1371/journal.pone.0071376 PMID: 23951151.

34. Patsopoulos NA, Barcellos LF, Hintzen RQ, Schaefer C, van Duijn CM, Noble JA, et al. Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects. PLoS Genetics. 2013; 9(11):e1003926. https://doi.org/10.1371/journal.pgen.1003926 PMID: 24278027.

35. Regnell SE, Lernmark A. Early prediction of autoimmune (type 1) diabetes. Diabetologia. 2017; 60(8):1370–81. Epub 2017/05/28. https://doi.org/10.1007/s00125-017-4308-1 PMID: 28550517.

36. Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nature Reviews Disease Primers. 2017; 3:17016. https://doi.org/10.1038/nrdp.2017.16 PMID: 28358037.